Results 61 to 70 of about 160,542 (279)

Pembrolizumab-induced necrotizing diaphragmatic myositis

Pembrolizumab, an anti-PD1 antibody, is increasingly used for the treatment of non-small cell lung cancer. We report a severe and poorly described adverse effect of this therapy: necrotizing myopathy with diaphragmatic and myocardial involvement.
Noemí Vidal, Enric Prats, Carla Marco, David Rodríguez-Plaza   +3 more
core   +1 more source

Renal toxicities associated with pembrolizumab

, 2019
International audienceObjective : Expanded clinical experience with patients treated by pembrolizumab has accumulated. However, renal toxicities associated with this anti-programmed cell death 1 agent are poorly described because kidney histology is ...
Michels, Judith, Izzedine, Hassan, Varga, Andrea, Malka, David, Soria, Jean-Charles, Champiat, Stéphane, Marabelle, Aurélien, Mathian, Alexis, Amoura, Zahir, Picard, Cécile, Routier, Emilie, Kaaki, Sihem, Goujon, Jean-Michel, Lambotte, Olivier, Brochériou, Isabelle, Mateus, Christine, Quellard, Nathalie, Leary, Alexandra, Michot, Jean-Marie   +18 more
core   +1 more source

Immunogenicity of pembrolizumab in patients with advanced tumors

Journal for ImmunoTherapy of Cancer, 2019
Background Pembrolizumab is a potent, humanized, monoclonal anti–programmed death 1 antibody that has demonstrated effective antitumor activity and acceptable safety in multiple tumor types. Therapeutic biologics can result in the development of antidrug
Marianne J. H. van Vugt, Julie A. Stone, “Rik” H. J. M. M. De Greef, Ellen S. Snyder, Leslie Lipka, David C. Turner, Anne Chain, Mallika Lala, Mengyao Li, Seth H. Robey, Anna G. Kondic, Dinesh De Alwis, Kapil Mayawala, Lokesh Jain, Tomoko Freshwater   +14 more
doaj   +1 more source

Targeting KDM3B Elicits Anti‐tumor Immunity by Alleviating SHP1–mediated STING Suppression in Triple–Negative Breast Cancer

Advanced Science, EarlyView.
P3FI–90 treatment targets KDM3B, reshapes the epigenetic landscape, and suppresses SHP1 expression, thereby activating STING–TBK1–IRF3–type I IFN signaling pathway. Consequently, CD8+ T cells are recruited to the tumor site and activated to produce IFN–γ and GZMB, leading to the killing of TNBC cells.
Xiaolong Wang, Wenhao Li, Yifei Wang, Ning Zhang, Bing Chen, Wenjing Zhao, Lijuan Wang, Dan Luo, Qifeng Yang   +8 more
wiley   +1 more source

Tumor Lysis Syndrome Due to Pembrolizumab Use in Metastatic Nasopharyngeal Carcinoma

In this case, we report tumor lysis syndrome (TLS) in a patient with metastatic nasopharyngeal carcinoma treated with pembrolizumab. There are only a few studies reporting the development of TLS associated with pembrolizumab, but this is the first report
ÇAĞLAR, ALPEREN AKANSEL, Mehmet Bilici, Alperen Akansel Çağlar, BÜYÜKBAYRAM, MEHMET EMİN, Aykut Turhan, TEKİN, SALİM BAŞOL, Zekeriya Hannarici, TURHAN, AYKUT, Salim Başol Tekin, ÇOBAN EŞDUR, PINAR, Mehmet Emin Büyükbayram, HANNARİCİ, ZEKERİYA, Pınar Çoban Eşdur, BİLİCİ, MEHMET   +13 more
core   +1 more source

Pembrolizumab for early triple-negative breast cancer

, 2020
Background: Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer.
McArthur, H., Dent, R., Schmid, P., Harbeck, N., Cardoso, F., Foukakis, T., Aktan, G., Pusztai, L., Kümmel, S., Hui, R., O'Shaughnessy, J., Cortes, J., Takahashi, M., Park, Y. H., Bergh, J., Karantza, V., Denkert, C., Fasching, P. A., Zhao, J., Jia, L., Untch, M.   +20 more
core   +1 more source

A Foundation Model Based CT Biomarker for Non‐Invasive Prediction of Response to Neoadjuvant Immunochemotherapy in Non‐Small Cell Lung Cancer

Advanced Science, EarlyView.
This study introduces a foundation model‐based biomarker for risk stratification of pathological response in non‐small cell lung cancer. A Vision Mamba super‐resolution model standardizes heterogeneous CT images. A multi‐task Swin Transformer then fine‐tunes a pre‐trained lung foundation model to jointly optimize tumor segmentation and response ...
Yanglan Xu, Shuchang Zhou, Qin Peng, Xiao Bao, Xiaodan Ye, Ahmet Görkem Er, Tong Tong, Mirabela Rusu, Yajia Gu, Mailin Chen, Jing Gong   +10 more
wiley   +1 more source

Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study

BMC Cancer
Background Indoleamine 2,3- dioxygenase 1 (IDO1) is an immunosuppressive enzyme that has been correlated with shorter disease-specific survival in patients with urothelial carcinoma (UC).
Andrea Necchi, Michiel S. Van der Heijden, Dmytro Trukhin, Avivit Peer, Howard Gurney, Boris Y. Alekseev, Francis X. Parnis, Raya Leibowitz, Maria De Santis, Petros Grivas, Jason Clark, Mihaela Munteanu, Ritesh Kataria, Calvin Jia, Arjun V. Balar, Ronald de Wit   +15 more
doaj   +1 more source

Placental Site Trophoblastic Tumor Acquires Immune Functions by Incorporating Host Maternal Genes

Advanced Science, EarlyView.
PSTT cells, through cell fusion with B cells, incorporate abundant non‐inherited maternal genes that are detectable by DNIMA. These hybrid cells acquire immunotherapy‐resistant genetic changes and increase the expression of B cell‐derived immune‐related molecules such as Ig, HLA, LILRB, SIGLEC10, and so on, creating an immunotolerant environment around
Kyosuke Kagami, Masanori Ono, Yasunari Mizumoto, Tatsuhito Kanda, Takashi Iizuka, Takiko Daikoku, Shin‐ichi Horike, Akira Hattori, Akihito Horie, Sachiko Minamiguchi, Tomoko Fujiwara, Kazuyoshi Hosomichi, Atsushi Tajima, Hirokazu Usui, Kaoru Abiko, Hiroshi Fujiwara   +15 more
wiley   +1 more source

89Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs

Journal for ImmunoTherapy of Cancer, 2020
Background To better predict response to immune checkpoint therapy and toxicity in healthy tissues, insight in the in vivo behavior of immune checkpoint targeting monoclonal antibodies is essential.
Annelies Jorritsma-Smit, Elisabeth G E de Vries, Danique Giesen, Marjolijn N Lub-de Hooge, Elly L van der Veen, Linda Pot-de Jong   +5 more
doaj   +1 more source